{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:02:40Z","timestamp":1789761760377,"version":"4.0.1"},"reference-count":17,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.5582\/ddt.2025.01048","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:07:24Z","timestamp":1750961244000},"page":"210-211","source":"Crossref","is-referenced-by-count":13,"title":["Acoltremon: The first TRPM8 agonist approved for the treatment of dry eye disease"],"prefix":"10.5582","volume":"19","author":[{"given":"Yang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification report. Ocul Surf. 2017; 15:276-283.","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hakim FE, Farooq AV. Dry eye disease: An update in 2022. JAMA. 2022; 327:478-479.","DOI":"10.1001\/jama.2021.19963"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wan KH, Chen LJ, Young AL. Depression and anxiety in dry eye disease: A systematic review and meta-analysis. Eye (Lond). 2016; 30:1558-1567.","DOI":"10.1038\/eye.2016.186"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Safir M, Twig G, Mimouni M. Dry eye disease management. BMJ. 2024; 384:e77344.","DOI":"10.1136\/bmj-2023-077344"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zhuang-Yan A, Syed YY. Perfluorohexyloctane ophthalmic solution: A review in dry eye disease. Drugs. 2024; 84:441-448.","DOI":"10.1007\/s40265-024-02016-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. O&apos;Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019; 30:166-178.","DOI":"10.1097\/ICU.0000000000000569"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jones L, Downie LE, Korb D, <i>et al<\/i>. TFOS DEWS II management and therapy report. Ocul Surf. 2017; 15:575-628.","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Clayton JA. Dry eye. N Engl J Med. 2018; 378:2212-2223.","DOI":"10.1056\/NEJMra1407936"},{"key":"9","unstructured":"9. US FDA. FDA-approved Drugs. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/217370Orig1s000ltr.pdf<\/i> (accessed June 1, 2025)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yang JM, Li F, Liu Q, Ruedi M, Wei ET, Lentsman M, Lee HS, Choi W, Kim SJ, Yoon KC. A novel TRPM8 agonist relieves dry eye discomfort. BMC Ophthalmol. 2017; 17:101.","DOI":"10.1186\/s12886-017-0495-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yang JM, Wei ET, Kim SJ, Yoon KC. TRPM8 channels and dry eye. Pharmaceuticals (Basel). 2018; 11:125.","DOI":"10.3390\/ph11040125"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Parra A, Madrid R, Echevarria D, Del Olmo S, Morenilla-Palao C, Acosta MC, Gallar J, Dhaka A, Viana F, Belmonte C. Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. Nat Med. 2010; 16:1396-1399.","DOI":"10.1038\/nm.2264"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yoon HJ, Kim J, Yang JM, Wei ET, Kim SJ, Yoon KC. Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: A pilot study. J Clin Med. 2021; 10:250.","DOI":"10.3390\/jcm10020250"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Valdes-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, Navia JC, Galor A. Recent United States developments in the pharmacological treatment of dry eye disease. Drugs. 2024; 84:549-563.","DOI":"10.1007\/s40265-024-02031-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wirta DL, Senchyna M, Lewis AE, Evans DG, McLaurin EB, Ousler GW, Hollander DA. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022; 26:166-173.","DOI":"10.1016\/j.jtos.2022.08.003"},{"key":"16","unstructured":"16. TRYPTYR (acoltremon) ophthalmic solution. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217370s000lbl.pdf<\/i> (accessed June 16, 2025)."},{"key":"17","unstructured":"17. Alcon Inc. Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye. <i>https:\/\/alcon.widen.net\/s\/gvp6nqtpql\/ar-15512_global-press-release_final<\/i> (accessed June 1, 2025)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/3\/19_2025.01048\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:49:24Z","timestamp":1751676564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/3\/19_2025.01048\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01048","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"2025.01048"}}